drug_type
RELEVANT_DRUG
intervention_type
CAR-T cell therapy
drug_description
Autologous BCMA-directed CAR T-cell therapy administered intravenously; patient T cells are engineered to express a chimeric antigen receptor targeting BCMA on myeloma cells, activating T-cell cytotoxicity and cytokine release to kill BCMA-positive plasma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Ciltacabtagene Autoleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that binds BCMA on myeloma plasma cells. CAR engagement activates the T cells to proliferate, release cytokines, and mediate perforin/granzyme-dependent cytotoxic killing of BCMA-positive cells.
drug_name
Ciltacabtagene autoleucel (cilta-cel)
nct_id_drug_ref
NCT06550895